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Purpose: Lacritin is a naturally occurring human glycoprotein secreted from the lacrimal gland 
as a component of tears. Preliminary studies suggest that down-regulation of lacritin is associated 
with various ocular diseases, such as dry eye syndrome and blepharitis. Thus, lacritin shows 
potential as a new topical therapeutic for the treatment of ocular diseases. Previous studies have 
shown that recombinant human lacritin, when topically applied to rabbit eyes, promotes basal 
tearing. Antibodies produced against the terminal ends of human lacritin were used to develop a 
clinical immunodiagnostic assay that detect and quantify lacritin in human tear samples. In order 
to develop lacritin as a human therapeutic, it must be tested in an animal model system prior to 
human clinical trials. Previous studies have revealed that canines also suffer from dry eye 
syndrome, having clinical parallels to humans in the diagnosis and treatment of this disease. The 
assay used to detect lacritin in human tears was used to detect a lacritin ortholog in canine tears. 
The canine lacritin ortholog was cloned, sequenced, and a recombinant protein purified for the 
development of a canine lacritin immunoassay. This work describes the development of an 
immunodiagnostic ELISA assay to quantitate canine lacritin in tear samples and implementation 
of this assay to compare levels of canine lacritin in tears from normal and dry eye animals. 
Methods: Rabbit polyclonal antibodies were produced against a synthetic peptide with the 
amino acid sequence of the first 20 amino acids of canine lacritin and purified over a Protein A 
Sepharose column. The antibodies were titrated against recombinant canine lacritin to produce 
an indirect Enzyme Linked Immunosorbent Assay (ELISA). The components of this assay, 
including the dilutions of the primary detection antibodies and secondary HRP-conjugated 
antibody, were optimized via checkerboard titrations. The ELISA was then used to detect and 
quantitate lacritin in healthy canine tear samples and tear samples from canines clinically 
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diagnosed with dry eye. Western blot analysis was used to visualize lacritin in canine tear 
samples. 
Results: An N-terminus peptide of amino acids identical to canine lacritin was synthesized and 
used to immunize rabbits (cLACRT N-Term-KLH/BSA). Titration of the 10 week anti-cLACRT 
NT and 10 week anti-cLACRT NT Protein A purified antisera (from rabbit 6924) detected 
lacritin at 0.1 to 1,000 ng, while the preimmune serum (from rabbits 6924 and 6925) did not 
detect lacritin. Levels of lacritin in healthy and dry eye canine tear samples were analyzed by an 
indirect ELISA in triplicate using the standard curve of recombinant canine lacritin to express 
values as nanograms of lacritin per 10 ng total tear protein. Immunoanalysis of normal and dry 
eye tears detected an average of 3.5 ng lacritin in normal tears and an average of 0.7 ng lacritin 
in tears collected from dogs diagnosed with dry eye. Western blot analysis using the 10 week 
anti-cLACRT NT Protein A purified antiserum detected prominent bands in healthy tears, and 
faint or absent bands in dry eye tears. The preimmune serum did not detect any bands.   
Conclusions: An immunodiagnostic ELISA assay and Western blot analysis was successfully 
developed to quantitate and visualize lacritin in canine tear samples. Immunodiagnostic analysis 
and Western blot analysis shows that canine lacritin is down-regulated approximately 5 fold in 





Discovery, Structure, and Function of Lacritin 
In 2001, Dr. Gordon Laurie of the University of Virginia discovered and named lacritin, a 
naturally occurring human glycoprotein secreted from the lacrimal gland as a component of tears 
(Sanghi et al, 2001). A consortium was organized after the discovery of lacritin to investigate 
and characterize the biological properties of lacritin and develop new human therapeutics for 
ocular diseases. 
Lacritin is mitogenic, prosecretory, and when cleaved, has antimicrobial activities against 
Gram-positive and Gram-negative bacteria (McKown et al., 2014). It has a molecular weight of 
12.3 kDa and is composed of 119 amino acids following cleavage of the signal sequence (Ma et 
al., 2008). After its production in the lacrimal gland, it exits the gland through acinar secretory 
granules, and travels through ducts to the eye’s surface (Ma et al., 2008). Studies have shown 
that lacritin stimulates secretion after binding to corneal epithelial cells (Sanghi et al., 2001) and 
promotes new tear production when topically applied to the eyes of rabbits (Samudre et al., 
2011).   
Purpose of the Canine Lacritin Investigation 
Tears are crucial for the health and function of the cornea (Ofria et al., 2009). Deficiency 
of tears, Keratoconjunctivitis sicca (KCS) or dry eye syndrome, is commonly observed in 
humans; 25% of patients visiting ophthalmic clinics and over 10% of adults aged 65 and older 
have the disease (Moss et al., 2009). Research has shown that lacritin is down-regulated in 
patients with dry eye (Srinivasan, et al., 2012) and in patients with blepharitis, inflammation of 
the eye associated with KCS (Tsai et al., 2006). KCS has also been observed in canines and may 
be diagnosed as acute or chronic (Reddan, 2011). The successful treatment of dry eye in canines 
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may provide a suitable animal model system for the development of lacritin as a new treatment 
for dry eye in humans. 
Previous Foundational Research 
Orthologs of lacritin have previously been characterized in non-human primates 
(Nakajima et al., 2007) and horses (Laurie et al., 2012). The prevalence of dry eye in canines 
warranted an examination of the canine genome for sequence similarities and canine tear 
samples to detect a lacritin ortholog. The human lacritin gene sequence (LACRT) and canine 
chromosome 27 were aligned using Ensembl, a genomic search tool. The Clustal Omega tool 
was used to comparatively analyze the human gene, determine exons of the proposed canine 
gene, and predict protein products. Analysis using Clustal W2 revealed that there is 35% amino 
acid identity between the human protein and the putative canine ortholog protein, which is 
encoded by a gene 368 nucleotides in length (Laurie et al., 2012).   
 To determine whether antibodies specific to human lacritin could detect the canine 
ortholog, canine tear samples were obtained from healthy animals by Dr. Ian Herring at the VA-
MD Regional College of Veterinary Medicine, Virginia Tech. Two human anti-lacritin 
polyclonal rabbit antibodies were used to detect lacritin in the canine tear samples. The N-
terminal antibody was produced against a synthetic peptide corresponding to the first 19 amino 
acids of the N-terminus of human lacritin and the C-terminal antibody was produced against a 
purified recombinant truncation mutant protein lacking the first 65 amino acids of the N-
terminus of human lacritin. Research including an indirect ELISA (Figure 1) and Western blot 
analysis (Figure 2), was done on the canine tears using the human antibodies. Interestingly, the 




Figure 1. ELISA standard curve and canine tear sample results. A) Recombinant human 
lacritin standard curve with anti C-terminal and anti N-terminal lacritin antibodies. B) ELISA 
determination of the amount of lacritin in nanograms in canine tear samples (Tate et al., 2013). 
 
Figure 2. Western blot analysis of multiple canine tear samples and a single human tear 
sample. The tear samples were separated using SDS PAGE, transferred to nitrocellulose, and 
incubated with anti N-terminal antibodies. OD designates right eye and OS designates left (Tate, 
et al., unpublished results).  
Considering the low sequence homology between human and canine lacritin, an effort 
was made to increase the sensitivity of the assays to be used in future studies. The canine lacritin 
gene was cloned and sequenced (Figure 3), and subsequently inserted in a pTYB2 vector, 
producing the plasmid pAC1. The plasmid was introduced in E. coli and the resulting protein 
was expressed and purified (Figure 4). The amino acid sequence of the protein was determined 




Figure 3. Cloning and sequence analysis of the canine lacritin gene. A) Predicted plasmid 
map resulting from the insertion of the cLac gene into the vector pTYB2, producing the plasmid 
pAC1. B) Forward sequencing results of pAC1 using the T7 universal promoter. C) DNA 




Figure 4. SDS gel of the purification of recombinant canine lacritin. Lane 1: Molecular 
weight standards. Lane 2: Cleared lysate after induction. Lane 3: Chitin affinity chromatography 
of canine lacritin. Lane 4: DEAE Sepharose 140 mM elution of canine lacritin (Tate, et al., 




Figure 5. Amino acid sequence of recombinant canine lacritin (Tate, et al., 2013). The lightly 
shaded region is the sequence used to produce the N-terminal antisera and the darker shaded 
region is the sequence used to produce the C-terminal antisera.  
 
The ELISA Immunoassay 
 There are multiple distinct ELISA designs, and an indirect ELISA was chosen for 
development in this study. In the indirect ELISA, wells of a microtiter plate are coated with the 
antigen. The primary polyclonal antibodies are added to the wells and bind specifically to the 
antigen (Figure 6). The secondary antibodies conjugated to horseradish peroxidase (HRP) 
enzyme are added to the wells and bind specifically to the primary antibodies. After incubation 
and washing to remove unbound reagents, o-phenylenediamine dihydrochloride (OPD) substrate 
is added to each well and the HRP enzyme catalyzes a colorimetric reaction. The colorimetric 
reaction is read in a spectrophotometer and used to quantitate the antigen in the given sample 







Figure 6. Indirect ELISA assay. The antigen is bound to the wells first, followed by primary 
antibodies, secondary antibody conjugate, and finally a substrate that reacts with the conjugate 
and yields a colorimetric response. 
 
The primary objective of this research is to develop a canine specific ELISA 
immunodiagnostic assay to quantitate canine lacritin in tear samples and compare the tear lacritin 




Materials and Methods 
Tear Collection and Elution 
 Canine tear samples were obtained from Dr. Ian Herring at the VA-MD Regional College 
of Veterinary Medicine, Virginia Tech. Tear samples, designated 1 through 7 (OD/OS), were 
collected from seven healthy canines on wicks and processed as follows. Filter sterilized PBS 
(30 μL) was added to each wick and allowed to soak for 20 minutes followed by centrifugation 
at 13,000 rpm for 10 minutes and storage at 4°C. A subsequent collection of tear samples from 
healthy canines, designated A1 through A6 (OD/OS), was conducted. Tear samples, designated 
66, 59, and 44 (OD/OS), obtained from dogs clinically diagnosed with dry eye syndrome were 
also processed for analysis. 
Determination of Canine Tear Protein Concentration 
 The Thermo Scientific BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL) was 
used to determine the concentration of total protein in tear samples as recommended by the 
manufacturer. Microtiter plates were incubated for 30 minutes at 37˚C and absorbances read in a 
spectrophotometer at 570 nm (model 680; Bio-Rad, Hercules, CA). The standard protein 
concentrations were graphed against their absorbances and a line of best fit was plotted. The 
equation of the line of best fit was used to determine the concentration of total tear protein in 
each sample. 
Anti-N-Terminal Anti-Canine Lacritin Antisera Production and Protein A Purification 
The N-terminus peptide of canine lacritin EGDSSDPAPGAAAADPGGL (amino acids 1-
19 without signal peptide) was synthesized with >90% purity and conjugated to keyhole limpet 
hemocyanin/bovine serum albumin (KLH/BSA) by Bio-Synthesis, Inc. (Lewisville, TX). Two 
New Zealand white rabbits, designated 6924 and 6925, were immunized and serum was 
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collected over a 10 week period (Appendix A). Preimmune serum was collected before 
immunization and the final antiserum (anti-cLACRT N-Term [NT]) was collected after 10 
weeks. Protein A coupled with agarose beads (Bio-Rad Laboratories; Hercules, CA) was used to 
purify IgG antibodies from the anti-cLACRT NT antiserum. IgG antiserum was bound and 
washed with 140 mM NaCl phosphate buffered saline (PBS), pH 8.2. The purified IgG antiserum 
was eluted using 0.1 M glycine, pH 2.5, neutralized with 1 M Tris, pH 8.0, and dialyzed against 
PBS.  
The Indirect ELISA Immunoassay 
The following protocol describes the standard indirect ELISA developed for canine 
lacritin. Modifications to this protocol and specific dilutions used in different experiments are 
noted when presented. For the standard curve, lyopholized recombinant canine lacritin is 
resuspended in 100 μL of distilled water, diluted with coating buffer (4.53 mL of 1.0 M 
NaHCO3, 1.82 mL of 1.0 M Na2CO3, 93.65 mL dH2O) to 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 14, and 16 
ng, and 100 μL of each dilution is plated in triplicate. Tear samples are diluted in coating buffer, 
added in triplicate to the same microtiter plate as the standards, and incubated overnight at 4°C 
for antigen binding. Coated plates are washed three times with PBS plus 0.3% Tween20 (PBS-T) 
and 300 μL of blocking buffer (1% w/v BSA) is added to each well. Following incubation at 
37°C for one hour, plates are washed three times with PBS-T and 100 μL of primary antibodies 
diluted in PBS-T are added, followed by incubation at 37°C for one hour. After incubation, 
plates are washed three times with PBS-T and 100 μL of secondary HRP-conjugated goat anti-
rabbit IgG antibody (Thermo Scientific, Rockford, IL) diluted in PBS-T are added and incubated 
for one hour at 37°C. Following incubation, plates are washed three times with PBS-T, 100 μL 
of OPD substrate are added, and the plates are incubated in the dark for ten minutes at room 
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temperature. OPD substrate is prepared by combining 6.0 mL of 0.1 M C6H8O7, 6.5 mL of 0.2 M 
Na2HPO4, 12.5 mL dH2O, 10 μL H2O2, and two o-phenylenediamine dihydrochloride (OPD) 
tablets (Acros Organics, Geel, Belgium). Following development, absorbances are measured at 
415 nm and plotted against recombinant canine lacritin concentrations to generate a standard 
curve. Quantitation of canine tear lacritin was determined using the equation generated by the 
best fit standard curve. 
Antibody Specificity and Checkerboard Titration 
Preimmune, 10 week anti-cLACRT NT, and 10 week anti-cLACRT NT Protein A (PA) 
purified antibodies (6924) were titrated against recombinant canine lacritin to determine 
specificity. Canine lacritin was diluted from 0 ng/mL to 10,000 ng/mL in coating buffer.  
Primary antibody was diluted 1:800 and secondary antibody diluted 1:800 in PBS-T for the 
indirect ELISA. Preimmune and 10 week anti-cLACRT NT antibodies from rabbit 6925 were 
also titrated against recombinant canine lacritin to determine specificity. Primary antibodies were 
diluted from 1:100 to 1:1600 in PBS-T and the secondary HRP-conjugated goat anti-rabbit IgG 
antibody was diluted 1:1000 in PBS-T. 
 A checkerboard titration was performed to optimize the dilutions of primary and 
secondary antibodies used to create a standard curve. Recombinant canine lacritin was diluted to 
0, 1.25, 2.5, 5, 10, and 20 ng/mL in coating buffer and plated. Primary 10 week anti-cLACRT 
NT antibodies (from rabbit 6924) were diluted to 1:15,000 and 1:20,000 in PBS-T. The 
secondary antibody was diluted from 1:500 to 1:4000 in PBS-T, plated, and developed in the 
standard ELISA protocol. A checkerboard titration was also performed using the primary 10 
week anti-cLACRT NT PA purified antibodies (from rabbit 6924). Modifications to the protocol 
were limited to diluting the primary antibodies from 1:200 to 1:3200 in PBS-T and diluting the 
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secondary HRP-conjugated goat anti-rabbit IgG antibody to 1:1000 in PBS-T. A checkerboard 
titration was performed using the primary 10 week anti-cLACRT NT antibodies from rabbit 
6925 and the 10 week anti-cLACRT NT PA purified antibodies from rabbit 6925 with the 
following modifications: the primary antibodies were diluted from 1:1000 to 1:16,000 in PBS-T 
with the secondary antibody diluted to 1:1000 in PBS-T.   
ELISA Analysis of Canine Tear Samples 
The indirect ELISA was used to quantitate lacritin expression in canine tear samples. The 
14 canine tear samples (designated 1 through 7, OD and OS) were diluted to 0.5 µg/mL in 
coating buffer and plated in triplicate (100 µL). Samples 1 through 4 (OD/OS) were analyzed on 
one plate, and 5 through 7 (OD/OS) on a second plate each with standards for quantitation. Plates 
were developed with 10 week anti-cLACRT NT antibodies (from rabbit 6924) diluted 1:14,000 
and with secondary HRP-conjugated goat anti-rabbit IgG antibody diluted 1:500.  
Lacritin in canine tear samples 2, 4, 5, 6, and 7 (OD/OS) was also quantitated using the 
10 week anti-cLACRT NT PA purified antibodies (from rabbit 6924). The protocol was 
modified slightly; recombinant canine lacritin was diluted to 0, 2, 4, 6, 8, 10, 12, 14, and 16 ng 
and both the primary and secondary antibodies were diluted to 1:800 in PBS-T. The same 
experiment was conducted a second time using the PA purified antibodies and diluting the tear 
samples further to 0.25 µg/mL.   
Dry eye tear samples were analyzed for comparison with normal tear samples. Fresh 
normal tear samples, designated A1 through A6 (OD/OS), and dry eye tear samples, designated 
66, 59, and 44 (OD/OS), were diluted to 0.1 µg/mL in coating buffer and plated in triplicate. 
Normal tear samples A2, A4, A5, and A6 (OD/OS) were analyzed on one plate, and dry eye 
samples 66, 59, and 44 (OD/OS) with normal tear sample A1 (OD/OS) for comparison were 
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analyzed on a second plate. Primary antibody 10 week anti-cLACRT NT PA (from rabbit 6924) 
was diluted 1:800 and secondary HRP-conjugated goat anti-rabbit IgG antibody was diluted 
1:800. Bound antibody was measured at 415 nm and a standard curve was generated from which 
the amount of lacritin in the tear samples was extrapolated. 
SDS Polyacrylamide Gel Electrophoresis and Western Blot Analysis 
Western blot analysis was performed to visualize lacritin in the canine tear samples.  
Canine tear samples A1, A2, A4, A5, A6, 66, 59, and 44 (OD/OS) were subjected to sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Tear samples (10 µl) were 
prepared by adding 4 µL of 6X loading dye and boiling for five minutes. A 20 µL aliquot of each 
sample and 7 µL of protein ladder (Precision Plus Protein Kaleidoscope Standards, BioRad) 
were loaded on two Any kD™ Mini-PROTEAN® TGX™ Precast Gel filled with Tris-glycine 
buffer (Bio-Rad) and electrophoresed at 200 V. Once the samples reached the bottom of the gels, 
the gels were transferred to nitrocellulose membranes (Protran BA 83; Whatman, Dassel, 
Germany) to perform the Western blot analysis. The SDS gels, nitrocellulose membranes, filter 
pads, and filter paper were soaked in transfer buffer for five minutes. A Mini Trans-blot was 
assembled (Appendix B) to transfer the samples from the gel to the membranes and was allowed 
to run for 60 minutes at 100 V. The membranes were removed from the apparatus and washed 
overnight with PBS-T.   
The following day, blots were washed twice with PBS-T, 15 minutes each wash, and then 
incubated with 10 week anti-cLACRT NT PA purified antibodies (from rabbit 6924) diluted 
1:1,500 in PBS-T for one hour at room temperature. Following incubation, blots were subjected 
to four, 15 minute washes with PBS-T and incubated with the secondary HRP-conjugated goat 
anti-rabbit IgG antibody diluted 1:5,000 in PBS-T for one hour at room temperature. Blots were 
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washed twice with PBS-T for 15 minutes, twice with PBS for 15 minutes, and air dried for 
development.   
Blots were developed in a dark room via chemiluminescence with Pierce ECL Western 
Blotting Substrate (Thermo Fisher Scientific Inc., Rockford, IL). The membranes were soaked in 
substrate for one minute and covered in clear plastic wrap. X-ray film was exposed to the 
membranes for differing amounts of time to obtain adequate exposure. The exposed films were 
incubated with continuous agitation for 30 seconds in each of the following: developer solution, 






Determination of Canine Tear Protein Concentration 
 A BCA assay was performed to determine the levels of total protein concentration in 
eluted normal canine tear samples 1 through 7 (OD/OS), a second set of normal tear samples A1 
through A6 (OD/OS), and dry eye tear samples 66, 59, and 44 (OD/OS) (Figures 7 and 8, 
respectively). The range and mean for A1 through A6 were 3.23 mg/mL and 1.29 mg/mL, 
respectively. The range and mean for the dry eye samples were 2.38 mg/mL and 1.66 mg/mL, 
respectively. Figure 7 and 8 shows a summary of canine tear protein concentrations with an 



















A1 OD 1.64 66 OD 0.71 
A1 OS 1.38 66 OS 0.56 
A2 OD 1.82 59 OD 1.53 
A2 OS 2.35 59 OS 2.94 
A3 OD 2.10 44 OD 1.34 
A3 OS 4.10 44 OS 2.87 
A4 OD 1.58   
A4 OS 1.81   
A5 OD 2.54   
A5 OS 3.34   
A6 OD 0.86   
A6 OS 1.21   
Figures 7 – 8. Standard curve example and summary of tear protein concentrations.  
Detailed Figures 7 and 8 with raw data are shown in Appendix F. 
 
Anti-N-Terminal Anti-Canine Lacritin Antisera Production and Protein A Purification 
 Amino acids 1-19 of the N-terminus canine lacritin was synthesized and used to 
immunize rabbits to generate polyclonal antibodies. Pre-bleed samples were collected before 
immunization to serve as controls. Antiserum was collected four times, with the final antiserum 
collected 10 weeks after the final immunization. The resulting 10 week anti-cLACRT NT 
antibodies, 6924 and 6925, were purified over a Protein A column, generating an elution curve 
(Figure 9). The antibodies from 6924 yielded elution peaks at around 11 and 2.2 mg/mL in 
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Figure 9. Protein A purification of polyclonal antibodies. Antibodies were purified over a 
Protein A sepharose column and washed with PBS. Shown is purification of polyclonal 
antibodies 6924. Purification of both 6924 and 6925 are shown in Appendix F.  
 
Titration of Antibodies 
 Titrations of the 10 week anti-cLACRT NT and 10 week anti-cLACRT NT PA purified 
antibodies (from rabbit 6924) were performed to determine their specificity to canine lacritin. 
These titration curves were compared to the titration of the pre-bleed serum (from rabbit 6924) 
(Figure 10). Results indicate that both of the 10 week antibodies detected lacritin at coating 
levels of 0.1 to 1,000 ng. The pre-bleed serum did not detect lacritin. The anti-cLACRT NT 





Figure 10. Titration of 6924 antibodies. Recombinant canine lacritin diluted to 0, 0.1, 1, 10, 
100, and 1000 ng in 1X coating buffer. Primary and secondary antibodies diluted 1:800 in PBS-
T. Figure 10 with raw data is shown in Appendix F. 
 
Titrations of the preimmune serum and 10 week anti-cLACRT NT antibodies from rabbit 
6925 were also performed. The 10 week antibodies detected lacritin at coating levels of 0.1 to 
1,000 ng while the preimmune serum did not detect any lacritin (Appendix D). 
Checkerboard Titration of Antibodies 
Checkerboard titrations were performed on both the 10 week anti-cLACRT NT and 10 
week anti-cLACRT NT Protein A purified antibodies (from rabbit 6924) to optimize the 
dilutions of primary and secondary antibodies to be used to develop the indirect ELISA. The 
primary polyclonal antibodies were titrated against a standard curve of canine lacritin: 0, 1.25, 2, 
5, 10, and 20 ng. The results indicated that for the 10 week anti-cLACRT NT antisera, the 
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optimal dilution of the primary antibodies was 1:14,000 and the secondary 1:500 (Figure 11). 
 
Figure 11. Checkerboard titrations of 10 week anti-cLACRT NT antibodies from rabbit 
6924. Recombinant canine lacritin diluted to 0, 1.25, 2.5, 5, 10, and 20 ng. B) Primary antibody 
diluted 1:15,000, secondary diluted from 1:500 to 1:4000. D) Primary antibody diluted 1:20,000, 
secondary diluted from 1:500 to 1:4000. Figure 11 with raw data is shown in Appendix F. 
 
For the 10 week anti-cLACRT NT PA purified antisera (from rabbit 6924), the optimal 
dilution of the primary antibodies was 1:800 and the secondary 1:800 (Figure 12). 
 
Figure 12. Checkerboard titration of 10 week anti-cLACRT NT PA purified antibodies 
from rabbit 6924. Recombinant canine lacritin diluted to 0, 1.25, 2.5, 5, 10, and 20. B) Primary 
antibody diluted from 1:200 to 1:3,200 and secondary diluted to 1:1,000. Figure 12 with raw data 
is shown in Appendix F. 
 
 For the 10 week anti-cLACRT NT antisera (from rabbit 6925), the optimal dilution of 
primary antibodies was 1:800 and the secondary 1:800 (Appendix D). A checkerboard was also 
performed using 10 week anti-cLACRT NT PA purified antisera (from rabbit 6925), but the 
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optimal dilutions were not determined (Appendix D). With the components of the assay 
optimized, an indirect ELISA protocol was developed. 
Standard Curve of Antibodies 
 Once the optimal dilutions of the components of the assay were determined, a standard 
curve was performed before analysis of tear samples to ensure an R
2
 value of at least 0.97 could 
be produced. An R
2
 value of 0.9922 was produced for the 10 week anti-cLACRT NT antibodies 
from rabbit 6924 (Figure 13).  
 
 
Figure 13. Standard curve using 10 week anti-cLACRT NT antibodies from rabbit 6924.  
Recombinant canine lacritin diluted from 0 to 16 ng. Primary antibodies diluted to 1:14,000, and 
the secondary antibodies diluted to 1:500. Figure 13 with raw data is shown in Appendix F. 
 
10 week anti-cLACRT NT PA purified antibodies (from rabbit 6924) produced an R
2
 





Figure 14. Standard curve using 10 week anti-cLACRT NT PA purified antibodies from 
rabbit 6924. Recombinant canine lacritin diluted from 0 to 16 ng. Primary antibodies diluted to 
1:800 and secondary antibodies diluted to 1:800. Figure 14 with raw data is shown in Appendix 
F.   
 10 week anti-cLACRT NT antibodies (from rabbit 6925) produced an R
2
 value of 0.997 
and the 10 week anti-cLACRT NT PA purified antibodies (from rabbit 6925) produced an R
2
 
value of 0.9347 (Appendix E). Because the dilutions for the antibodies from rabbit 6924 were 
optimized, no further testing involving antibodies from rabbit 6925 was performed. 
ELISA Analysis of Canine Tear Samples 
An indirect ELISA was used to quantitate lacritin in canine tear samples. The assay was 
developed using 10 week anti-cLACRT NT antiserum (from rabbit 6924) as the primary 
antibody and the HRP-conjugated antibody as the secondary. An R
2
 value of at least 0.97 for the 
standard curve was required. The plate containing samples 1 through 4 (OD/OS) generated a 
standard curve of 0.9785 and the plate containing samples 5 through 7 (OD/OS) generated a 
standard curve of 0.9798 (Figure 15). Lacritin in the canine tear samples was quantitated in 
triplicate by using the standard curve to extrapolate and express values as nanograms of lacritin 
per 50 ng total tear protein (Figure 15). The tear samples comprised a range and mean of 10.71 
and 13.12 ng lacritin per 50 ng total tear protein, respectively. 
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The assay was also developed using 10 week anti-cLACRT NT PA purified antiserum 
(from rabbit 6924) as the primary antibody and the HRP-conjugated antibody as the secondary. 
Lacritin in the canine tear samples was again quantitated in triplicate by using the standard curve 
to express values as nanograms of lacritin per 50 ng total tear protein (Figure 16). The tear 
samples comprised a range and mean of 14.83 and 16.00 ng lacritin per 50 ng total tear protein, 
respectively. The canine tear samples were not analyzed using antibodies from rabbit 6925. 
Sample 
ng Lacritin/ 
50 ng Protein 
Sample 
ng Lacritin/ 
50 ng Protein 
1 OD 14.27 1 OD  
1 OS 14.39 1 OS  
2 OD 13.44 2 OD 18.03 
2 OS 14.00 2 OS 17.00 
3 OD 13.05 3 OD  
3 OS 10.11 3 OS  
4 OD 15.02 4 OD 19.94 
4 OS 16.31 4 OS 15.92 
5 OD 12.62 5 OD 15.98 
5 OS 5.60 5 OS 5.11 
6 OD 13.65 6 OD 16.16 
6 OS 13.80 6 OS 17.10 
7 OD 12.26 7 OD 17.16 
7 OS 15.20 7 OS 17.62 
 
Figures 15 - 16. Indirect ELISA analysis of canine tear samples 1 through 7 (OD/OS) 
diluted to 0.5 µg/mL. Figures 15 and 16 with raw data are shown in Appendix F. 
 
Ideal data would have had at least two standard curve data points above and below the 
calculated tear lacritin value. The data from both experiments normalizing the tear samples to 0.5 
µg/mL produced results that did not fit this criteria. Because of this, the assay was performed 
again using the 10 week anti-cLACRT NT PA purified antiserum (from rabbit 6924) as the 
primary antibody and the HRP-conjugated antibody as the secondary, but normalizing the tear 
samples to 0.25 µg/mL. Lacritin was quantitated in triplicate by using the standard curve to 





25 ng Protein 
Sample 
ng Lacritin/ 
25 ng Protein 
2 OD 13.60 2 OD 15.2 
2 OS 8.45 2 OS 8.80 
4 OD 11.33 4 OD 10.92 
4 OS 10.89 4 OS 10.65 
5 OD 5.90 5 OD 5.68 
5 OS -0.04 5 OS 0.38 
6 OD 8.33 6 OD 9.06 
6 OS 7.92 6 OS 8.22 
7 OD 8.01 7 OD 6.92 
7 OS 8.22 7 OS 7.92 
 
Figure 17. Indirect ELISA analysis of canine tear samples 2, 4, 5, 6, and 7 (OD/OS) diluted 
further to 0.25 µg/mL. Figure 17 with raw data is shown in Appendix F. 
 
An indirect ELISA was used to quantitate lacritin in fresh healthy canine tear samples 
and in dry eye tear samples. The assay was developed using 10 week anti-cLACRT NT PA 
purified antiserum (from rabbit 6924) as the primary antibody and the HRP-conjugated antibody 
as the secondary. The plate containing normal samples A2, A4, A5, and A6 (OD/OS) generated a 
standard curve of 0.9908, and a range and mean of 4.35 and 3.51 ng lacritin per 10 ng total tear 
protein, respectively (Figure 18). The plate containing dry eye samples 66, 59, and 44 (OD/OS) 
with normal sample A1 (OD/OS) generated a standard curve of 0.9931, and a range and mean of 












10 ng Protein 
Sample 
ng Lacritin/ 
10 ng Protein 
A2 OD 6.41 66 OD 0.33 
A2 OS 3.12 66 OS 2.61 
A4 OD 2.30 59 OD 3.17 
A4 OS 2.84 59 OS -0.46 
A5 OD 2.07 44 OD -0.18 
A5 OS 2.68 44 OS 0.41 
A6 OD 4.38 1 OD 8.63 
A6 OS 4.28 1 OS 5.12 
 
Figures 18 - 19. Indirect ELISA analysis of canine tear samples diluted to 0.1 µg/mL. 
Figures 18 and 19 with raw data are shown in Appendix F.   
 
The difference in lacritin quantity between the normal and dry eye tears was determined, 
the latter of which showed significant down-regulation (Figure 20). 
 
Figure 20. Summary of canine tear lacritin in normal (blue) and dry eye (red) tear samples as 
determined by indirect ELISA. 
 
Detection of Canine Tear Lacritin by Western Blot 
A Western blot was performed to detect lacritin in normal tear (A1, A2, A4, A5, and A6 
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tears, anti-cLACRT NT PA purified antiserum (from rabbit 6924) detected prominent bands at 
around 17 kD, corresponding to canine lacritin (Figure 21A). The Western blot of dry eye tears 
detected faint or no bands at 17 kD (Figure 21B). 
 
Figure 21. Western Blot analysis of normal and dry eye tears. A) Normal tear samples A2, 
A4, A5, and A6 (OD/OS). B) Dry eye tear samples 66, 59, and 44 (OD/OS) and normal tear 
sample A1 (OD/OS). The band corresponding to monomeric canine lacritin is seen at ~17 kD. 





 Lacritin is a naturally occurring human tear glycoprotein that is mitogenic, prosecretory, 
and when cleaved, has antimicrobial activity against bacteria. After its production in the lacrimal 
gland, it exits the gland through acinar secretory granules, and travels through ducts to the 
surface of the eye. Previous studies have shown that lacritin stimulates secretion after binding to 
corneal epithelial cells and promotes new tear production when topically applied to the eyes of 
rabbits. Tears are crucial for the health and function of the cornea. The deficiency of tears, 
Keratoconjunctivitis sicca (KCS), or dry eye syndrome, is frequently observed in humans. 
Research has shown that lacritin is down-regulated in patients with dry eye and blepharitis, 
inflammation of the eye associated with KCS. This has implicated lacritin as a possible 
therapeutic for ocular diseases. 
Dry eye syndrome has also been observed in canines. Thus, the successful treatment of 
dry eye in canines may provide a suitable animal model system for the treatment of dry eye in 
humans. The prevalence of dry eye in canines warranted an examination of the canine genome 
for sequence similarities and canine tear samples to detect a lacritin ortholog. The human lacritin 
gene (LACRT) and canine chromosome 27 were aligned using a genomic search tool. Analysis 
revealed that there is 35% amino acid identity between the human protein and the putative canine 
ortholog, which is encoded by a gene 368 nucleotides long. 
To determine whether antibodies specific to human lacritin could detect the canine 
ortholog, canine tear samples were obtained from healthy animals. Two human anti-lacritin 
polyclonal rabbit antibodies were used to detect lacritin in the canine tear samples. The N-
terminal antibody was produced against a synthetic peptide corresponding to the first 19 amino 
acids of the N-terminus of human lacritin and the C-terminal antibody was produced against a 
purified recombinant truncation mutant protein lacking the first 65 amino acids of the N-
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terminus of human lacritin. Research conducted on the canine tears using the human antibodies 
revealed that the N-terminal antibody detected lacritin in these samples, while the C-terminal 
antibody did not. 
Because there was low sequence homology between human and canine lacritin, an effort 
was made to increase the sensitivity of the assays to be used in future studies. The canine lacritin 
gene was cloned, sequenced, expressed in an E. coli vector, and the resulting protein was 
purified. Canine lacritin’s amino acid sequence was determined from the nucleotide coding 
sequence. The primary objective of this research was to develop an immunodiagnostic assay to 
quantitate canine lacritin in tear samples by generating polyclonal antibodies specific to canine 
lacritin. An indirect ELISA was chosen for development in this study as it has been used as an 
immunodiagnostic assay for human lacritin (Seifert et al., 2012). This diagnostic assay could 
help establish lacritin levels in healthy canines for comparison to those affected by dry eye 
syndrome.   
The first step in the development of the ELISA was antibody production. The N-terminus 
peptide of canine lacritin was synthesized and used to immunize two New Zealand white rabbits, 
designated 6924 and 6925. Preimmune serum was collected before immunization and the final 
antiserum, anti-cLACRT NT, was collected after 10 weeks. 
To increase their purity, the 10 week antibodies were subsequently purified using a 
Protein A column. The Protein A purified antibodies (from rabbit 6924) exhibited slightly lower 
binding affinity for lacritin than the 10 week antibodies. Both 6924 and 6925 10 week anti-
cLACRT NT antibodies displayed high binding compared to the preimmune serum, which was 
to be expected.   
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Once the antibodies were determined to be specific to canine lacritin, the components of 
the indirect ELISA had to be optimized. Checkerboard titrations were used to help determine the 
optimal dilutions of the primary polyclonal antibodies and the secondary HRP conjugated 
antibody. As a negative control, a row with no antigen, was included in every trial. The dilutions 
of the primary and secondary antibodies were serially diluted to determine the linear range on the 
titration curve. The optimal dilutions for each primary antibody were determined. However, the 
dilutions for 10 week anti-cLACRT NT PA purified antibodies (from rabbit 6925) were not 
optimized because optimization of the other antibodies had been determined and were found to 
be suitable for the planned experiments.  
After the optimal dilutions of the primary and secondary antibodies were determined, 
standard curves were performed to ensure that an R
2
 value of at least 0.97 could be generated. 
This criteria was met for the 10 week anti-cLACRT NT antibodies (from rabbit 6924), 10 week 
anti-cLACRT NT PA purified antibodies (from rabbit 6924), and the 10 week anti-cLACRT NT 
antibodies (from rabbit 6925). The standard curve using 10 week anti-cLACRT NT PA purified 
antibodies (from rabbit 6925) did not produce an R
2
 value of at least 0.97 because the dilutions 
were not optimized by the checkerboard titration, and thus were not included in further testing.   
After the dilutions of the primary and secondary antibodies were determined and an R
2
 
value of at least 0.97 could be produced, a working indirect ELISA protocol was developed. This 
protocol was then used to quantitate the amount of lacritin in the canine tear samples. The assay 
was developed using the 10 week anti-cLACRT NT antibodies (from rabbit 6924) to analyze the 
original tear samples 1 through 7 (OD/OS) and the 10 week anti-cLACRT NT PA purified 
antibodies (from rabbit 6924) to analyze the original tear samples 2, 4, 5, 6, and 7 (OD/OS). All 
tear samples were normalized to 0.5 µg/mL. Both experiments produced comparable results, but 
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an ideal dataset would have had at least two standard curve data points above and below the 
calculated tear lacritin value. Because this criterion was not met in either experiment, another 
trial was conducted using the 10 week anti-cLACRT NT PA purified antibodies (from rabbit 
6924) but diluting the tears to 0.25 µg/mL. The data produced from this trial supported the 
previous data.   
The ELISA was then developed using the 10 week anti-cLACRT NT PA purified 
antibodies (from rabbit 6924) to analyze new normal tear samples A1, A2, A4, A5, and A6 
(OD/OS) and dry eye tear samples 66, 59, and 44 (OD/OS). All tear samples were normalized to 
0.1 µg/mL. There was a substantial difference observed in canine lacritin quantity between the 
normal and dry eye tears. The dry eye tears had little to no detectable canine lacritin, 
demonstrating significant down-regulation.  
Western blotting was used to visualize canine lacritin in the normal and dry eye tear 
samples. The 10 week anti-cLACRT NT PA purified antibodies (from rabbit 6924) detected 
canine lacritin in the normal tears and very little to no canine lacritin was detected in the dry eye 
tears. The results from the Western blots supported the data from the ELISA analysis of tear 
samples.  
The immunodiagnostic ELISA assay developed in this work was used to compare tear 
canine lacritin levels in healthy animals with those affected by dry eye syndrome. The ELISA 
immunoassay and Western blot analysis reveals that canines clinically diagnosed with dry eye 
syndrome have significantly down-regulated tear lacritin. This finding is extremely important, as 
this supports the feasibility of lacritin as a topical therapeutic for the treatment of dry eye. Future 
clinical animal studies will test topically applied canine lacritin on healthy animals to determine 
safety and enhanced tear secretion followed by clinical testing of lacritin as a treatment for 
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canine dry eye. Successful treatment of canine dry eye with lacritin may result in a new animal 






Antibody Production Schedule 
 
October 30, 2013 
 
Robert L. McKown 
James Madison University 
 
Dear Dr. McKown, 
Your full service Custom Antibody Project immunization protocol has been initiated on 
10/29/2013.  The following table outlines the bleed schedule: 
 
Project No.                           Immunogen Name         Rabbit Nos. 
AB1412-1                               BSYN 6924 and 6925 
 
 
Bleed No.  Date  Yield (serum/rabbit)  Project duration 
0(pre-immune)  10/29/13  2-3ml           0 days 
1(week 6)  12/10/13  15ml         42 days 
2(week 8)  12/24/13  15ml         56 days 
3(week 10)  01/07/14  15ml         70 days 
     
The project can be continued beyond Bleed No. 3.  We can continue the boost/bleed maintenance 
schedule of the project for a charge of $200/month/rabbit.  The project may be continued until 
the entire available antigen is used.  At any time, you may also request exsanguination of any 
rabbit for an additional 50-100ml of crude serum.  The charge for this service is $1/ml (max. 
charge $100/rabbit) of crude serum shipped.  There is a shipping charge for any additional 
shipments past the 3
rd
 bleed. 
Bleed Nos. 0, 1, and 2 will be shipped together few days after the 8th week bleed.  The last bleed 
will be shipped to you following the 10
th
 week unless affinity purification was added to the 
project.  You must complete the necessary analysis on this shipment of serum and confirm 
by fax or e-mail your desire to continue with the project within three days of termination 
(day 75).  We will terminate your project if we do not hear from you prior to day 75. 
If you desire to continue the project or wish to exsanguinate an animal, please give the 
appropriate payment instructions with your request (i.e. PO number). 
Should you have any questions regarding our services, please call 1-800-227-0627 ext. 103, e-

















Figure 22.  BCA Analysis of canine tear samples 1 OD to 7 OD.  A) Raw data produced from 
BCA at 570 nm.  B) Standard curve generated from raw data with an R
2
 value of 0.9967.  C) 






Figure 23. BCA Analysis of canine tear samples 1 OS to 7 OS. A) Raw data produced from 
BCA at 570 nm. B) Standard curve generated from raw data with an R
2
 value of 0.9973. C) Tear 













Figure 24. Titration of 6924 antibodies. Recombinant canine lacritin diluted to 0, 0.1, 1, 10, 
100, and 1000 ng in 1X coating buffer. Primary antibodies diluted from 1:100 to 1:1600 in PBS-
T and secondary diluted to 1:1000 in PBS-T. A) Raw data produced from titration curve for pre-
bleed serum at 415 nm. B) Measured absorbances were plotted against ng lacritin. C) Raw data 
using primary anti-cLACRT NT antibody at 415 nm. D) Measured absorbances were plotted 





Figure 25. Checkerboard titrations of 10 week anti-cLACRT NT antibodies from 6925.  
Recombinant canine lacritin diluted to 0, 1.25, 2.5, 5, 10, and 20 ng in 1X coating buffer. A) 
Raw data with primary antibody diluted 1:1000 in PBS-T, secondary diluted from 1:1000 to 
1:16,000 in PBS-T, and read at 415 nm. B) Measured absorbances were plotted against ng 









Figure 26. Standard curve using10 week anti-cLACRT NT antibodies from rabbit 6925.  
Recombinant canine lacritin diluted from 0 to 16 ng in 1X coating buffer, the primary diluted to 
1:8,000 in PBS-T, and the secondary to 1:1000 in PBS-T. A) Raw data produced at 415 nm. B) 





Figure 27. Standard curve using 10 week anti-cLACRT NT PA purified antibodies from 
rabbit 6925. Recombinant canine lacritin diluted from 0 to 16 ng in 1X coating buffer, the 
primary diluted to 1:4000 in PBS-T, and the secondary to 1:1000. A) Raw data produced at 415 








Figure 7A. BCA Analysis of healthy canine tear samples 1 through 6, OD and OS. A) Raw 
data produced from BCA at 570 nm. B) Standard curve generated from raw data with an R
2
 
value of 0.9954. C) Tear sample concentrations were extrapolated using the standard curve and 











Figure 8A. BCA Analysis of dry eye canine tear samples 66, 59, and 44, OD and OS. A) 
Raw data produced from BCA at 570 nm. B) Standard curve generated from raw data with an R
2
 
value of 0.9935. C) Tear sample concentrations were extrapolated using the standard curve and 







Figure 9A. Protein A purification of polyclonal antibodies A) 6924 and B) 6925. Antibodies 





















Figure 10A. Titration of 6924 antibodies. Recombinant canine lacritin diluted to 0, 0.1, 1, 10, 
100, and 1000 ng in 1X coating buffer. Primary and secondary antibodies diluted 1:800 in PBS-
T. A) Raw data produced from titration curve for pre-bleed, 10 week anti-cLACRT NT, and 10 
week anti-cLACRT NT PA purified antisera at 415 nm. B) Measured absorbances were plotted 





Figure 11A. Checkerboard titrations of 10 week anti-cLACRT NT antibodies from rabbit 
6924. Recombinant canine lacritin diluted to 0, 1.25, 2.5, 5, 10, and 20 ng in 1X coating buffer. 
A) Raw data with primary antibody diluted 1:15,000 in PBS-T, secondary diluted from 1:500 to 
1:4000 in PBS-T, and read at 415 nm. B) Measured absorbances were plotted against ng lacritin. 
C) Raw data with primary antibody diluted 1:20,000 in PBS-T, secondary diluted from 1:500 to 







Figure 12A. Checkerboard titration of 10 week anti-cLACRT NT PA purified antibodies 
from rabbit 6924. A) Recombinant canine lacritin diluted to 0, 1.25, 2.5, 5, 10, and 20 ng. B) 




Figure 13A. Standard curve using 10 week anti-cLACRT NT antibodies from rabbit 6924.  
Recombinant canine lacritin diluted from 0 to 16 ng in 1X coating buffer, the primary antibodies 
diluted to 1:14,000, and the secondary to 1:500 in PBS-T. A) Raw data produced at 415 nm. B) 






Figure 14A. Standard curve using 10 week anti-cLACRT NT PA purified antibodies from 
rabbit 6924. Recombinant canine lacritin diluted from 0 to 16 ng in 1X coating buffer, the 
primary antibodies diluted to 1:800 in PBS-T, and the secondary to 1:800 in PBS-T. A) Raw data 











Figure 15A. Indirect ELISA analysis of canine tear samples 1 through 7 (OD/OS) diluted to 
0.5 µg/mL. Recombinant canine lacritin was diluted to 0, 0.5, 1, 2, 4, 6, 8, 10, 12 14, and 16 ng 
in 1X coating buffer. A) Raw data at 415 nm. B) A standard curve was generated with an R
2
 
value of 0.9785. C) This standard curve was used to extrapolate the amount of lacritin in canine 
tear samples 1 through 4 (OD/OS). D) Raw data at 415 nm. E) A standard curve was generated 
with an R
2
 value of 0.9798. F) This standard curve was used to extrapolate the amount of lacritin 
in canine tear samples 5 through 7 (OD/OS).   
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Figure 16A. Indirect ELISA analysis of canine tear samples 2, 4, 5, 6, and 7 (OD/OS) 
diluted to 0.5 µg/mL. Recombinant canine lacritin was diluted to 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 
and 16 ng in 1X coating buffer. A) Raw data at 415 nm. B) A standard curve was generated with 
an R
2
 value of 0.9856. C) This standard curve was used to extrapolate the amount of lacritin in 










Figure 17A. Indirect ELISA analysis of canine tear samples 2, 4, 5, 6, and 7 (OD/OS) 
diluted further to 0.25 µg/mL. Recombinant canine lacritin was diluted to 0, 2, 4, 6, 8, 10, 12, 
14, and 16 ng in 1X coating buffer. A) Raw data at 415 nm. B) A standard curve was generated 
with an R
2
 value of 0.9812. C) This standard curve was used to extrapolate the amount of lacritin 












Figure 18A. Indirect ELISA analysis of healthy canine tear samples 2, 4, 5, and 6 (OD/OS) 
diluted to 0.1 µg/mL. Recombinant canine lacritin was diluted to 0, 2, 4, 6, 8, 10, and 12 ng in 
1X coating buffer. A) Raw data at 415 nm. B) A standard curve was generated with an R
2
 value 
of 0.9908. C) This standard curve was used to extrapolate the amount of lacritin in canine tear 














Figure 19A. Indirect ELISA analysis of dry eye canine tear samples 66, 59, and 44 (OD/OS) 
diluted to 0.1 µg/mL. Recombinant canine lacritin was diluted to 0, 2, 4, 6, 8, 10, and 12 ng in 
1X coating buffer. A) Raw data at 415 nm. B) A standard curve was generated with an R
2
 value 
of 0.9931. C) This standard curve was used to extrapolate the amount of lacritin in canine tear 
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